A medical device company which focuses on designing and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
MELA has developed a state of the art device in detecting early stage melanoma, and is a significant improvement over current methods-- the eyes-- which will reduce unnecessary biopies. The product is FDA approved, and has sold off primarily due to tax sellling and significant manipulation by short-sellers. Valuation absurdly cheap. Stock could easily break $3.00 as distribution, sales, and marketing increase in first six months of 2013. Easy buyout candidate in the $8-$10 dollar range.